Audit: QRS - Thymulin for Health & Longevity

Audit conducted on 06/08/2026 14:25 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A
8.7	If no [stop_items] are present the section is left empty	N/A

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A
9.7	If no [caution_items] are present the section is left empty	N/A

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢

Issues 06/08/2026 14:25

Pass rate 100.00%. No issues found.

Issues 06/08/2026 14:17

1. 4.2 / 4.3 — Key Interaction labels not verbatim: Three Key Interactions labels are abbreviated rather than taken verbatim from the ER bold labels — “Over-the-counter acid suppressants and antacids” (ER line 357) and “Over-the-counter iron and calcium supplements” (ER line 359) both lose the “Over-the-counter” qualifier at QRS lines 594–595, and “Rapamycin and other mechanistic-target-of-rapamycin inhibitors” (ER line 369) loses “other” at QRS line 600.

Fixes 06/08/2026 14:17

1. 4.2 / 4.3 — Key Interaction labels restored verbatim: Restored the ER’s bold labels in the Key Interactions gate — “Acid suppressants and antacids” → “Over-the-counter acid suppressants and antacids”, “Iron and calcium supplements” → “Over-the-counter iron and calcium supplements”, and “Rapamycin and mechanistic-target-of-rapamycin inhibitors” → “Rapamycin and other mechanistic-target-of-rapamycin inhibitors”.

Issues 06/08/2026 14:10

1. 4.2 — Protocol labels re-cased, not verbatim: All three protocol cell labels are title-cased instead of carrying the ER’s bold label verbatim — line 449 “The Historical Clinical Dosing” (ER 410 “The historical clinical dosing”), line 463 “Competing Approach Two — Zinc Repletion to Reactivate Endogenous Thymulin” (ER 414 lowercase), line 477 “Timing of Administration” (ER 418 “Timing of administration”).

Fixes 06/08/2026 14:10

1. 4.2 — Protocol labels restored to ER casing: Re-cased all three protocol cell labels to the ER’s bold labels verbatim — “The Historical Clinical Dosing” to “The historical clinical dosing”, “Competing Approach Two — Zinc Repletion to Reactivate Endogenous Thymulin” to “Competing approach two — zinc repletion to reactivate endogenous thymulin”, and “Timing of Administration” to “Timing of administration”.

Issues 06/08/2026 14:03

1. 4.2 / 4.3 — Protocol labels not ER-verbatim: action_1_label (QRS line 449) reads “Historical Clinical Dosing” where the ER bold label is “The historical clinical dosing:” (ER line 410), and action_2_label (QRS line 462) reads “Competing Approach” where the ER bold label is “Competing approach two — zinc repletion to reactivate endogenous thymulin:” (ER line 414).

Fixes 06/08/2026 14:03

1. 4.2 / 4.3 — Protocol labels restored to ER wording: action_1_label changed from “Historical Clinical Dosing” to “The Historical Clinical Dosing” and action_2_label from “Competing Approach” to “Competing Approach Two — Zinc Repletion to Reactivate Endogenous Thymulin”, matching the ER bold labels at ER lines 410 and 414.

Issues 06/08/2026 13:50

1. 4.5 — Sheet overruns one A4 page: At the @media print A4 box the sheet’s content column is 1033 px tall, but the populated sheet renders to roughly twice that; the Key Interactions gate (lines 590–604, ~25 rendered lines), the Monitoring Why and Target cells and monitoring_cadence (lines 660–814), the protocol and time-to-effect sub cells (lines 455–533), and qualitative_item_1 (lines 823–826) all carry more text than their per-section budget allows.

Fixes 06/08/2026 13:50

1. 4.5 — Key Interactions gate condensed: Trimmed the example-drug lists on nine of the thirteen caution items (e.g., “Over-the-counter acid suppressants and antacids (omeprazole, esomeprazole, calcium carbonate, magnesium hydroxide)” to “Acid suppressants and antacids (omeprazole, calcium carbonate)”), cutting the gate from ~25 to ~18 rendered lines while keeping all thirteen items and at least one example per list.
2. 4.5 — Contraindications gate condensed: Shortened four stop items to two rendered lines each (e.g., “any time post-transplant, particularly first 12 months” to “any time, especially first 12 months”; “especially with prior grade 3 or higher immune-related adverse events” to “especially prior grade 3+ immune-related events”), preserving every time window, severity class, and threshold.
3. 4.5 — Monitoring cells reduced to single lines: Shortened six Why cells and two Target cells (e.g., “Confirms functional copper status rather than total copper” to “Confirms functional, not total, copper status”; “Absolute neutrophil count 1.8–7.0 ×10⁹/L” to “Neutrophils 1.8–7.0 ×10⁹/L”), removing roughly eight wrapped lines from the eleven-row table.
4. 4.5 — Monitoring cadence tightened: Rewrote monitoring_cadence from 385 to ~340 characters by dropping redundant qualifiers (“before any dosing” to “before dosing”, “on maintenance”, “site review and symptom check” to “site and symptom check”) while keeping every interval stated in the ER.
5. 4.5 — Protocol and time-to-effect sub-cells tightened: Condensed all six sub cells (e.g., “The rheumatoid arthritis trials assessed response at three months. Nothing supports a perceptible effect within days.” to “Rheumatoid arthritis trials assessed response at three months. Nothing supports an effect within days.”).
6. 4.5 — Qualitative item shortened: Reduced qualitative_item_1 from “Frequency, duration, and severity of minor infections across a full season, against the same period in prior years” to “Frequency, duration, and severity of minor infections versus prior seasons”.

Issues 06/08/2026 13:44

1. 4.2 / 4.3 — Key Interaction labels paraphrased: Three ER bold labels are not carried over verbatim: “Antibiotics chelated by zinc” became “Zinc-chelated antibiotics” (line 594), and “Over-the-counter” was dropped from “Over-the-counter acid suppressants and antacids” (line 597) and “Over-the-counter iron and calcium supplements” (line 598).
2. 4.5 — Sheet overflows one A4 page: The combined length of the 11-row monitoring table with its four-line cadence paragraph, the 13-item Key Interactions gate, the seven qualitative items carrying trailing rationale clauses, and the three-line protocol sub-texts pushes the sheet well past a single A4 page.
3. 10.4 — Bare ordinal as protocol label: [action_2_label] at line 463 reads “Competing Approach Two”, an ordinal that refers to an ER list the sheet never shows, so the label conveys nothing to a reader of the QRS.

Fixes 06/08/2026 13:44

1. 4.2 / 4.3 — Key Interaction labels restored verbatim: “Zinc-chelated antibiotics” was changed back to the ER label “Antibiotics chelated by zinc”, and “Over-the-counter” was reinstated on both “Over-the-counter acid suppressants and antacids” and “Over-the-counter iron and calcium supplements”.
2. 10.4 — Bare ordinal replaced in protocol label: [action_2_label] was changed from “Competing Approach Two” to “Competing Approach”, removing the ordinal that referred to an ER list the sheet never shows.
3. 4.5 — Sheet condensed toward the A4 budget: The seven qualitative items were stripped of their trailing rationale clauses, the monitoring cadence and the marker_9 rationale were shortened, all three protocol sub-texts and the injection-route time-to-effect sub-text were tightened, and two Contraindication items were trimmed while keeping every threshold and qualifier.

Issues 06/08/2026 13:32

1. 1.3 / 8.5 — Immunosuppressant scope dropped: Contraindication item 2 (QRS line 578) lists “Maintenance immunosuppressants (ciclosporin, tacrolimus, methotrexate, azathioprine, mycophenolate)” as an unqualified contraindication, but the ER scopes it as “Absolute contraindication in transplant recipients” (ER line 343), so the QRS extends it to anyone taking methotrexate, azathioprine or mycophenolate for a non-transplant indication.

Fixes 06/08/2026 13:32

1. 1.3 / 8.5 — Immunosuppressant scope restored: Contraindication item 2 changed from “Maintenance immunosuppressants (ciclosporin, tacrolimus, methotrexate, azathioprine, mycophenolate)” to “Maintenance immunosuppressants in transplant recipients (ciclosporin, tacrolimus, methotrexate, azathioprine, mycophenolate)”, restoring the ER’s population qualifier.

Issues 06/08/2026 13:29

1. 2.6 / 2.9 — Imperative addresses the reader: The Protocol cell [action_2_sub] (QRS line 470) opens with the imperative “Correct zinc status and let the body’s own peptide become active”, which instructs the reader instead of presenting evidence.
2. 4.2 / 4.3 — Protocol label not the ER label: [action_2_label] (QRS line 464) is “Competing Route”, an invented paraphrase; the ER’s bold label for that bullet is “Competing approach two — zinc repletion to reactivate endogenous thymulin” (ER line 414).

Fixes 06/08/2026 13:29

1. 2.6 / 2.9 — Imperative removed from Protocol cell: [action_2_sub] changed from “Correct zinc status and let the body’s own peptide become active.” to “Correcting zinc status lets the body’s own peptide become active.”
2. 4.2 / 4.3 — Protocol label aligned with the ER: [action_2_label] changed from the invented “Competing Route” to “Competing Approach Two”, taken from the ER bullet label “Competing approach two — zinc repletion to reactivate endogenous thymulin”.